drugset
Drugs / Second generation CAR-T cells
last change Jun 2022 re-read 3 minutes ago

Second generation CAR-T cells

Cell therapy targets CD19

Developed for
acute lymphoblastic leukemia · B-cell non-Hodgkin lymphoma
Investigated by
Jingzhou Central Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan Sian Medical Technology Co., Ltd · Xiangyang Central Hospital · People Hospital Of Yichang · The First People's Hospital of Yuhang District

Trials 2

today NCT03366324 · Ph 1/2 NCT02965092 · Ph 1/2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03366324 May 2016 → Jan 2021 B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia Wuhan Sian Medical Technology Co., Ltd Unknown No outcome recorded
Phase 1/2 NCT02965092 Dec 2015 → Jan 2021 acute lymphoblastic leukemia Wuhan Sian Medical Technology Co., Ltd Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Second generation CAR-T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT03366324 ↗
1

NCT02965092 ↗
Action Deplete “recognize tumor associated antigen and kill tumor cells specifically” NCT02965092 ↗
Modality Cell therapy “Chimeric antigen receptor (CAR)-modified T cells (CAR-T cells)” NCT02965092 ↗
Target CD19 “Chimeric antigen receptor T (CAR-T) cells targeting CD19” PMID 35799791 ↗ Jun 2022